George Budwell
George Budwell, Ph.D., is a contributing Biotechnology and Technology Analyst at The Motley Fool, covering disruptive innovators in healthcare, defense, and artificial intelligence, and writing on portfolio theory, dividend stocks, and value investing. Prior to The Motley Fool, George was a freelance medical and science writer for various organizations, as well as an independent consultant for multiple life sciences-oriented hedge funds. In a former life, he was an evolutionary biologist, having completed two postdoctoral fellowships at Kyoto University and Illinois State University, respectively. He holds a Ph.D. in Evolutionary Biology from Tulane University and a B.S. (pre-med) from Loyola University. Fun fact: George is an avid golfer, nature enthusiast, and proud father of four.
Recent Articles by George Budwell

3 No-Brainer AI Stocks to Buy Right Now

Is Rigetti Computing Stock a Buy?

Is IonQ Stock a Buy?

Is D-Wave Quantum Stock Still a Buy?

2 eVTOL Stocks to Load Up On This Week

10 AI Stocks I'd Buy Without Hesitation

2 Incredible Growth Stocks to Buy Hand Over Fist

Is Nvidia Stock a Bargain?

2 No-Brainer Growth Stocks to Buy in June

3 Best Growth Stocks to Buy in June

Why I Own These 9 Vanguard ETFs

Is Amgen Stock a Buy?

2 AI Stocks to Buy Hand Over Fist Right Now

Is CoreWeave Stock Still a Buy After Its 200% Rally?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.